FindTrial
Sign In

ZD4054

DRUG13 trials

Sponsors

AstraZeneca, Aarhus University Hospital, University of Wisconsin, Madison, Cardiff University, The Christie NHS Foundation Trust

Conditions

HealthyHealthy VolunteersHepatic ImpairmentLung CancerMetastasisMetastatic Breast CancerNon Small Cell Lung CancerProstate Cancer

Phase 1

Pharmacokinetics, Safety & Tolerability of ZD4054 (Zibotentan) in Subjects With Normal, Mild, Moderate and Severe Hepatic Impairment
CompletedNCT00672581
AstraZenecaHepatic Impairment
Start: 2008-04-30End: 2009-03-31Target: 32Updated: 2010-09-28
Drug Interaction Study to Asses Multiple Doses of ZD4054 (Zibotentan)
CompletedNCT00709553
AstraZenecaHealthy
Start: 2008-07-31End: 2008-08-31Target: 12Updated: 2010-09-28
Food Effect Study of a Single Dose of ZD4054 (Zibotentan)
CompletedNCT00710047
AstraZenecaHealthy Volunteers
Start: 2008-06-30End: 2008-08-31Target: 30Updated: 2010-11-15
Four-period Crossover Study to Assess the Effects of Single Oral Doses of ZD4054 (Zibotentan) (10mg and 30mg) on QTc Interval
CompletedNCT00713336
AstraZenecaHealthy
Start: 2008-06-30End: 2008-11-30Target: 40Updated: 2010-09-28
Relative Bioavailability Study in Healthy Male Subjects for ZD4054 (Zibotentan) Immediate Release Tablets.
CompletedNCT00713791
AstraZenecaHealthy
Start: 2008-06-30End: 2008-08-31Target: 20Updated: 2010-11-15

Phase 2

ZD4054 (Zibotentan) Phase II Non-Small Cell Lung Cancer Study
CompletedNCT00745875
AstraZenecaLung Cancer, Non Small Cell Lung Cancer
Start: 2008-08-31End: 2010-01-31Updated: 2012-06-06
A Safety Study of ZD4054 in Prior Chemotherapy Treated Patients With Metastatic Hormone-resistant Prostate Cancer
TerminatedNCT01000948
Aarhus University HospitalMetastasis, Prostate Cancer
Start: 2009-10-31End: 2011-07-31Updated: 2014-01-08
ZD4054 With Positron Emission Tomography/Magnetic Resonance Imaging (PET/MRI) for Prostate Cancer
TerminatedNCT01119118
University of Wisconsin, MadisonProstate Cancer
Start: 2010-04-30End: 2011-11-30Updated: 2019-11-21
Carboplatin With or Without ZD4054 in Patients With Metastatic Breast Cancer
WithdrawnNCT01134497
Cardiff UniversityMetastatic Breast Cancer
End: 2011-08-16Updated: 2018-05-22

Phase 3

A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Hormone Resistant Prostate Cancer With Bone Metastases
CompletedNCT00554229
AstraZenecaProstate Cancer
Start: 2007-11-30End: 2011-08-31Updated: 2016-02-08
A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) and Docetaxel in Metastatic Hormone Resistant Prostate Cancer
CompletedNCT00617669
AstraZenecaProstate Cancer
Start: 2008-01-31End: 2011-07-31Updated: 2012-09-10
A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Non-metastatic Hormone Resistant Prostate Cancer
TerminatedNCT00626548
AstraZenecaProstate Cancer
Start: 2008-01-31End: 2011-05-31Updated: 2012-09-03

Unknown Phase

Window Study of ZD4054 in Metastatic Prostate Cancer
NCT01168141
The Christie NHS Foundation TrustMetastasis, Prostate Cancer
Start: 2009-07-31End: 2010-09-30Target: 30Updated: 2010-07-23

Related Papers

Development and validation of MOSPROC, an easily applicable predictive score of mortality for patients with prostate cancer.
Journal of Clinical Oncology2024-05-292 citations
Profiling of clinically relevant subgroups of asymptomatic or mild-symptomatic metastatic castration-resistant prostate cancer (mCRPC) patients using PSA and testosterone levels and deep learning.
Journal of Clinical Oncology2022-06-01
A deep learning framework (DLF) to identify clinical predictors of disease progression and mortality in metastatic castration-resistant prostate cancer (mCRPC) patients treated with docetaxel/prednisone (DP).
Journal of Clinical Oncology2022-06-01
Abstract 228: A precision dosing application for patients treated with docetaxel and G-CSF
Cancer Research2021-07-011 citations
A precision dosing application for prostate cancer patients treated with docetaxel and G-CSF.
Journal of Clinical Oncology2021-05-201 citations
Differential effect of body mass index (BMI) on outcomes of patients treated with docetaxel in prostate cancer: An exploratory analysis.
Journal of Clinical Oncology2021-02-201 citations
Abstract 677: A precision dosing application for prostate cancer chemotherapy
Cancer Research2019-07-011 citations
Abstract 677: A precision dosing application for prostate cancer chemotherapy
Bioinformatics, Convergence Science, and Systems Biology2019-07-01
External validation of a prognostic model for overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC).
Journal of Clinical Oncology2019-05-20
Detection of previously unidentified metastatic disease as a leading cause of screening failure in a phase III trial of zibotentan versus placebo in patients with nonmetastatic, castration resistant prostate cancer.
2012-05-1233 citations
Pharmacokinetics and tolerability of zibotentan (ZD4054) in subjects with hepatic or renal impairment: two open-label comparative studies.
2011-03-1719 citations
An open-label, randomized, single-center, two-period, phase I, crossover study of the effect of zibotentan (ZD4054) on the pharmacokinetics of midazolam in healthy male volunteers.
2010-07-014 citations